FinnCap reaffirmed their corporate rating on shares of Avacta Group (LON:AVCT) in a research note issued to investors on Monday.

Avacta Group stock opened at GBX 41.50 ($0.54) on Monday. Avacta Group has a fifty-two week low of GBX 40 ($0.52) and a fifty-two week high of GBX 98 ($1.28).

In other news, insider Tony Peter Gardiner bought 8,196 shares of the company’s stock in a transaction dated Monday, December 31st. The shares were acquired at an average cost of GBX 31 ($0.41) per share, with a total value of £2,540.76 ($3,319.95).

About Avacta Group

Avacta Group Plc offers reagents and therapeutics based on Affimer technology for diagnostic and research applications in the United Kingdom. It operates through two segments, Life Sciences and Animal Health. The company's custom Affimer products are also used in drugs and biomarkers discovery in biotech research and development.

See Also: Asset Allocation, Balancing Your Investments

Receive News & Ratings for Avacta Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avacta Group and related companies with MarketBeat.com's FREE daily email newsletter.